FDA Drug Application (202229) for ACAMPROSATE CALCIUM by GLENMARK GENERICS

Back to FDA Applications sponsored by GLENMARK GENERICS

Application Number202229
Product Number001
FormTABLET, DELAYED RELEASE;ORAL
Dosage333MG
Product Market Status Prescription
Therapeutic Equivalence Evaluation Code AB Products meeting necessary bioequivalence requirements
Reference Drug
Drug NameACAMPROSATE CALCIUM
Active IngredientACAMPROSATE CALCIUM

Active IngredientCount
List of drugs with Active Ingredient ACAMPROSATE CALCIUM2


Back to FDA Applications sponsored by GLENMARK GENERICS